Testosterone Metabolism & Clearance
Hepatic Conjugation, 5-Alpha Reduction, Aromatization, and Excretion
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (endogenous metabolism)
Reference only. Not medical advice.
What can go wrong
Conditions or drugs that alter hepatic metabolism, and genetic variation in conjugating and converting enzymes, can shift testosterone and its active metabolites. Historic 17-alpha-alkylated oral androgens illustrate how altering the molecule to survive first-pass metabolism introduced liver toxicity.
This is something to take to a clinician. The Atlas can tell you what is known about testosterone metabolism & clearance in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testosterone is cleared mainly by the liver through conjugation (glucuronidation and sulfation) to water-soluble metabolites excreted in urine, alongside peripheral conversion to DHT (5-alpha-reductase) and estradiol (aromatase). The liver's extensive first-pass metabolism is why ordinary oral testosterone is ineffective and why earlier oral 17-alpha-alkylated androgens were hepatotoxic; modern oral undecanoate and injectable esters are designed to bypass it.
What the body does to testosterone, and why oral testosterone fought the first-pass effect for decades.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
After acting on tissues, testosterone is largely inactivated in the liver to glucuronide and sulfate conjugates and excreted renally. In target tissues it is amplified to DHT by 5-alpha-reductase or converted to estradiol by aromatase before those metabolites are themselves cleared. Esterification (cypionate, enanthate, undecanoate) slows release and absorption, altering apparent half-life without changing the underlying metabolic fate.
Why the route, not just the dose, shapes the experience
Identical molecules behave differently by route because of metabolism. Injected esters create depots that release over days; oral undecanoate uses lymphatic absorption to dodge the liver; transdermals deliver steadily but with more skin 5-alpha-reduction to DHT. The same total dose can therefore yield different DHT and estradiol exposure depending on how it enters the body.
Replacement is not the same as a cycle
At replacement doses, metabolic clearance keeps DHT and estradiol within physiologic bounds. At supraphysiologic/anabolic doses, more substrate is pushed through aromatase and 5-alpha-reductase, raising estradiol and DHT exposure and contributing to gynecomastia, acne, and other dose-dependent effects.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Testosterone (trough/peak per formulation)
- Estradiol where clinically indicated
- Hematocrit and standard TRT labs
What people get wrong
Often saidA pill of plain testosterone would work like an injection
ActuallyNo. Oral testosterone is largely destroyed by first-pass hepatic metabolism, which is why special formulations or non-oral routes are required.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Compared with discussing dose alone, accounting for route and metabolism explains much of the variation in DHT/estradiol side-effect profiles between formulations.
At a glance
- Major clearance
- Hepatic glucuronidation/sulfation, urinary excretion
- Active conversions
- DHT via 5-alpha-reductase; estradiol via aromatase
- First-pass problem
- Plain oral testosterone is rapidly inactivated
- Detection
- Urinary metabolites and T/epitestosterone ratio in anti-doping
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testosterone Metabolism & Clearance. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.